RABL3

RABL3 is a small G-protein-fold GTPase that couples RAS prenylation control to cell proliferation, immune development, and cancer susceptibility (PMID:31406347, PMID:32220963). It interacts with the prenylation chaperone RAP1GDS1/SmgGDS, and a truncating mutant accelerates KRAS prenylation in a RAS-dependent manner to drive proliferation, linking RABL3 to dysregulated RAS activity (PMID:31406347). Structurally, RABL3 homodimerizes through the effector-binding surfaces of each monomer; a hypomorphic in-frame deletion forces switch I into a β-strand configuration that still permits dimerization but distorts the switch I–interswitch–switch II effector module (PMID:32220963). RABL3 is essential for development and immunity: homozygous loss is embryonic lethal in mice, while the hypomorphic allele causes profound lymphopenia spanning B, T, and NK lineages with impaired cytolytic activity, and it acts genetically upstream of its effector GPR89, which it binds and stabilizes (PMID:32220963). In human cancer cells RABL3 promotes proliferation, survival, motility, and chemoresistance, acting at least in part through activation of the FAK/AKT signaling pathway (PMID:20596630, PMID:33438143). The catalytic GTPase cycle of RABL3 and the precise mechanism linking its effector module to RAS prenylation have not been characterized in the available corpus.

1. 2010 Medium

   Established that RABL3 is a functional driver of cancer cell phenotypes rather than a passive marker, by showing its expression level controls proliferation, survival, drug resistance, and motility.

   Evidence Overexpression and siRNA knockdown with proliferation/motility assays and FAK phosphorylation Western blots in HeLa and MDA-MB-231 cells

   PMID:20596630

   Open questions at the time

   • Single-lab correlation of FAK phosphorylation without direct biochemical link
   • Does not establish how a small GTPase engages FAK
   • No in vivo validation in this study
2. 2019 High

   Connected RABL3 to RAS biology by identifying its physical interaction with the prenylation chaperone SmgGDS and showing a truncating mutant accelerates KRAS prenylation, defining a mechanism for cancer susceptibility.

   Evidence Mass spectrometry interaction mapping, transcriptomics, and proliferation/rescue assays in a heterozygous rabl3 mutant zebrafish model

   PMID:31406347

   Open questions at the time

   • Mechanism by which RABL3 modulates SmgGDS chaperone activity not resolved
   • Whether wild-type RABL3 normally restrains prenylation unclear
   • Direct enzymatic role of RABL3 GTPase cycle not defined
3. 2020 High

   Defined the structural basis of RABL3 function by solving its crystal structure, revealing effector-surface-mediated homodimerization and explaining how the hypomorphic deletion remodels the switch I effector module.

   Evidence X-ray crystallography and solution-phase dimerization assays with in vivo mouse genetic validation

   PMID:32220963

   Open questions at the time

   • Functional role of homodimerization in vivo not directly tested
   • Nucleotide-binding/hydrolysis state in the structure not detailed here
   • How conformational change alters specific effector binding not measured
4. 2020 High

   Demonstrated RABL3 is essential for development and immunity, establishing physiological loss-of-function phenotypes distinct from its oncogenic gain-of-function role.

   Evidence Mouse knockout (embryonic lethal) and ENU hypomorphic allele with flow cytometry across lineages and MCMV infection assays

   PMID:32220963

   Open questions at the time

   • Cellular/molecular cause of embryonic lethality unknown
   • Whether lymphoid defect reflects altered RAS prenylation untested
   • Cell-intrinsic vs extrinsic origin of lymphopenia not resolved
5. 2020 Medium

   Placed GPR89 downstream of RABL3 in lymphoid development by showing RABL3 binds and stabilizes GPR89 and that a Gpr89 mutant phenocopies the Rabl3 hypomorph.

   Evidence Co-immunoprecipitation/association assay and reciprocal genetic epistasis with an ENU-induced Gpr89 mutant in mice

   PMID:32220963

   Open questions at the time

   • Molecular consequence of GPR89 stabilization unknown
   • Whether GPR89 acts as a canonical GTPase effector untested
   • Single-study association without reciprocal biochemical validation
6. 2021 Medium

   Reinforced FAK signaling as a functional output of RABL3 by showing pharmacological FAK inhibition reverses RABL3-driven tumor phenotypes through the FAK/AKT axis.

   Evidence shRNA knockdown, overexpression, FAK inhibitor rescue, and xenograft assays in oral squamous cell carcinoma cells

   PMID:33438143

   Open questions at the time

   • Direct molecular link between RABL3 and FAK activation not defined
   • Relationship between FAK/AKT output and the RAS-prenylation mechanism unclear
   • Single-lab, single-cancer-type validation

• Whether RABL3 functions as a classical nucleotide-cycling GTPase, and how its SmgGDS/RAS-prenylation activity, GPR89 effector axis, and FAK/AKT output are mechanistically unified, remains unresolved.
• No characterization of RABL3 GTP binding/hydrolysis or GEF/GAP regulation
• No mechanism connecting RAS prenylation control to FAK/AKT signaling
• Whether the GPR89 and RAS-prenylation arms are independent or convergent unknown